Impact of Type of Hypomethylating Agent (HMA) Used on Outcomes of Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) - a Large, Multicenter, Retrospective Analysis
Year: 2023
Type: conference-abstract
Source: Blood
Authors: Jan Philipp Bewersdorf, Tariq Kewan, Ondrej Blaha, Maximilian Stahl, Najla H Al Ali, Amy E. DeZern, Mikkael A. Sekeres, Geoffrey L Uy, Hetty E. Carraway, Pinkal Desai, Elizabeth A. Griffiths, Eytan M. Stein, Andrew M. Brunner, Christine M. McMahon, Joshua F. Zeidner, Michael R. Savona, Jessica M. Stempel, Namrata Sonia Chandhok, Rahul Ramaswamy, Gail J. Roboz, Benjamin Rolles, Eunice S. Wang, Amyah C. Harris, Maria L Amaya, Hayley Hawkins, Justin Grenet, Carmelo Gurnari, Rory M. Shallis, Zhuoer Xie, Jaroslaw P. Maciejewski, David A Sallman, Matteo Giovanni Della Porta, Rami S. Komrokji, Amer M. Zeidan
Institutions: Memorial Sloan Kettering Cancer Center, Yale University, Yale Cancer Center, Moffitt Cancer Center, Johns Hopkins University, University of Miami, Washington University in St. Louis, Cleveland Clinic, Weill Cornell Medicine, Roswell Park Comprehensive Cancer Center, Dana-Farber Cancer Institute, University of Colorado Anschutz, UNC Lineberger Comprehensive Cancer Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Sylvester Comprehensive Cancer Center, NewYork–Presbyterian Hospital, Brigham and Women's Hospital, Harvard University, IRCCS Humanitas Research Hospital, Smilow Cancer Hospital
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4389246792